Martha Lopez-Yurda

10PUBLICATIONS
105CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Apr 14, 2025
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

S L Aronson, B Thijssen, M Lopez-Yurda

|Sep 14, 2024
Histopathological response to chemotherapy and survival of mucinous type gastric cancer.

Irene A Caspers, Astrid E Slagter, Pauline A J Vissers

Pageof 2